UCB has filed a patent for dihydrocyclopenta-isoquinoline-sulfonamide derivatives, which can be used to treat disorders caused by IgE, such as allergic responses, non-allergic mast cell responses, and certain autoimmune responses. The patent claims a compound of formula (I) or a pharmaceutically acceptable salt thereof. GlobalData’s report on UCB gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights UCB SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on UCB, Human telomerase RT biomarker was a key innovation area identified from patents. UCB's grant share as of September 2023 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230303517A1) describes a compound and its pharmaceutically acceptable salts for the treatment or prevention of various disorders caused by IgE, including allergies, non-allergic mast cell responses, type 1 hypersensitivity, urticaria, and familiar sinus inflammation. The compound is represented by formula (I) and can have different substituents on the R1 and R4 positions. The patent also claims methods for the treatment or prevention of specific conditions, such as asthma, eczema, allergic rhinitis, eosinophilic granulomatosis with polyangiitis, aspirin exacerbated respiratory disease, and cutaneous T-cell lymphoma, by administering the compound to a patient in need. Additionally, the patent claims a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. The compound and its salts can be administered to patients in a therapeutically effective amount. The patent provides specific examples of compounds falling under formula (I) and their respective substituents. This patent could potentially lead to the development of new treatments for various allergic and inflammatory conditions.

To know more about GlobalData’s detailed insights on UCB, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies